No products in the cart.
Pre-made Atinumab biosimilar ( Whole mAb, anti-RTN4 therapeutic antibody, Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 Antibody) - benchmark reference antibody
Cat:GMP-Bios-ab-037
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Atinumab biosimilar, Whole mAb, Anti-RTN4 Antibody: Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
ATI 355, a monoclonal antibody product targeting the Nogo-A protein, is being developed by Novartis for the treatment of spinal cord injuries. Clinical.
| Products Name (INN Index) | Pre-Made Atinumab biosimilar, Whole mAb, Anti-RTN4 Antibody: Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 therapeutic antibody |
|---|---|
| INN Name | Atinumab |
| Target | RTN4 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Novartis |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Spinal cord injuries |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | RTN4 |
| Package |
Previous slide
Next slide
